A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides

American Journal of Clinical Pathology

Volumn 117, Issue 4, 2002, Pages 589-596

  Pickering, Jerry W ^a   Martins, Thomas B ^a   Greer, Ryan W ^a   Schroder, M Carl ^a   Astill, Mark E ^a   Litwin, Christine M ^a   Hildreth, Stephen W ^a   Hill, Harry R ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

ELISA; Enzyme linked immunosorbent assay; Luminex; Pneumococcal polysaccharide; Pneumococcal vaccine

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MULTIPLEXED FLUORESCENT MICROSPHERE IMMUNOASSAY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROTYPE; VACCINATION;

ANTIBODIES, BACTERIAL; BINDING, COMPETITIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN G; MICROSPHERES; POLYSACCHARIDES, BACTERIAL; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEROTYPING;

EID: 0036322989     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LMCH-C4Q2-VFL9-3T1A     Document Type: Article

References (23)

1. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis (RE9960)
2. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in the United States
3. Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers
4. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
5. Efficacy of a pneumococcal conjugate vaccine against acute otitis media
6. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S
7. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides
8. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay
9. Comparison of ELISA and RIA for measurement of pneumococcal antibodies before and after vaccination with 14-valent pneumococcal capsular polysaccharide vaccine
10. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization
11. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization
12. ELISA methodology for polysaccharide antigens: Protein coupling of polysaccharides for adsorption to plastic tubes
13. Enhancement by N- hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions
14. Modification of a direct enzyme-linked immunosorbent assay for the detection of immunoglobulin G and M antibodies to pneumococcal capsular polysaccharide
15. Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides
16. Serum antibodies to pneumococcal C polysaccharide in children: Response to acute pneumococcal otitis media or to vaccination
17. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods
18. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: Determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide
19. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
20. Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharide of Streptococcus pneumoniae in childhood
21. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults
22. Are enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?
23. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic